SHENZHEN, China, July 1 /PRNewswire-Asia/ -- Tongjitang Chinese Medicines Company (the "Company"; NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it filed its Annual Report on Form 20-F for the year ended December 31, 2009 with the Securities and Exchange Commission on June 30, 2010. The Annual Report on Form 20-F can be accessed via the investor relations section of the Company's website at http://www.tongjitang.com .
The Company will provide a hard copy of its Annual Report on Form 20-F, including audited financial statements, free of charge to its shareholders and ADS holders upon request. Requests should be directed to the Company's Investor Relations contact at 203-682-8200.
About Tongjitang Chinese Medicines Company
Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and Anhui Jingfang, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.
Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 36 other modernized traditional Chinese medicine products and 36 western medicines. Please visit http://www.tongjitang.com for more information.
For further information, please contact:
ICR, Inc.
Ashley M. Ammon or Christine Duan
Tel: +1-203-682-8200 (Investor Relations)
